One of the important announcements coming out of the American Diabetes Association’s 70th Scientific Sessions were the results of a little known NIH study titled, “The Healthy Study: Interventions to reduce early diabetes risk.” This may be a new model of how we can prevent our children from getting diabetes….
Read More »Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset Type 1 diabetes….
Read More »New Class of Drug for Type 2 Diabetes Acts Independently of Insulin
A new first in class drug getting close to approval to treat Type 2 diabetes showed the potential to help lower blood glucose levels through a different mechanism than current treatments, according to new studies….
Read More »Byetta + Lantus Improved Outcomes without Weight Gain or Hypoglycemia
Amylin and Eli Lilly announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTAA® (exenatide) injection added to Lantus® (insulin glargine)….
Read More »Improvement in Beta-Cell Function Observed after Three Years of BYETTA(R) Therapy
Amylin and Lilly announced the results of another study, comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy….
Read More »BYDUREON(TM) Safety and Tolerability Pooled Summary Data
Data from nearly 1,100 patients in DURATION-1, -2 and -3 trials showed BYDUREON was well-tolerated….
Read More »Extended Release Metformin Allows for Higher Doses
New clinical study shows patients with Type 2 diabetes may be able to tolerate higher doses of metformin using GLUMETZA….
Read More »HbA1c Variation by Race Weakens Its Exclusive Diabetes Diagnostic Power
African Americans have higher levels of glycated hemoglobin (HbA1c) than whites given the same blood glucose concentrations, and the difference is greater as glucose levels go up. Findings could affect the way physicians use hemoglobin A1c to test for diabetes in blacks….
Read More »Liver at 50% Greater Risk in Diabetes
Although the liver is often overlooked in diabetes, even newly-diagnosed cases carry a substantial risk of serious hepatic damage, researchers found….
Read More »Body Fat Linked to Diabetes Risk in Older People
To avoid Type 2 diabetes, seniors may need to watch their weight just as closely as younger individuals do, a prospective cohort study showed….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.